Development of plasma kallikrein selecti
β
Yoshio Okada; Yuko Tsuda; Mayako Tada; Keiko Wanaka; Akiko Hijikata-Okunomiya; U
π
Article
π
1999
π
Wiley (John Wiley & Sons)
π
English
β 340 KB
During the course of the development of active center-directed plasmin inhibitors, it was found that N-(trans-4-aminomethylcyclohexanecarbonyl)-lysine-4-methoxycarbonylanilide inhibited plasma kallikrein more potently than other enzymes such as plasmin, urokinase, and thrombin, although the inhibito